ARTICLE | Company News
Life Science Pharmaceuticals, Kyowa Hakko Kogyo Co. Ltd. deal
March 19, 2007 7:00 AM UTC
Life Science received exclusive worldwide rights to develop and market Kyowa's KW-2871 to treat malignant melanoma. Life Science plans to start a Phase II trial of the chimeric MAb against the GD3 ant...